Fifty-four percent of solid organ transplant recipients had antibody response after two doses of SARS-CoV-2 mRNA vaccine<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
TUESDAY, May 11, 2021 (HealthDay News) — Fifty-four percent of solid organ transplant recipients have an antibody response to two doses of an mRNA severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, according to a research letter published online May 5 in the Journal of the American Medical Association<\/em>.<\/p>\n Brian J. Boyarsky, M.D., Ph.D., from the Johns Hopkins University School of Medicine in Baltimore, and colleagues followed up with 658 transplant recipients without prior COVID-19 who completed the two-dose SARS-CoV-2 mRNA vaccine series between Dec. 16, 2020, and March 13, 2021, through April 13, 2021.<\/p>\n The researchers found that antibody was detectable in 15 percent of participants at a mean of 21 days after dose 1 and in 54 percent of participants at a median of 29 days after dose 2. Median antibody levels after dose 2 were 2.14 U\/mL and 1.23 arbitrary units among all participants. For those participants with an antibody response after dose 2, the median antibody levels were 142.1 U\/mL and 6.48 arbitrary units; corresponding levels were 34.7 U\/mL and 5.05 arbitrary units for those with no antibody response after dose 1 and >250 U\/mL and 9.23 arbitrary units for those with antibody response after dose 1. Of the 473 participants receiving antimetabolites, 8, 57, and 35 percent had an antibody response after doses 1 and 2, no antibody response after dose 1 or dose 2, and no antibody response after dose 1 but a response after dose 2.<\/p>\n “These data suggest that a substantial proportion of transplant recipients likely remain at risk for COVID-19 after two doses of mRNA vaccine,” the authors write.<\/p>\n Two authors disclosed financial ties to the biopharmaceutical industry.<\/p>\n